Immunofluorescent analysis of c-Abl (green) showing staining in the cytoplasm of NIH-3T3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a c-Abl monoclonal antibody (Product # MA5-14398) in 3% BSA-PBS at a dilution of 1:50 and incubated overnight at 4°C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant Abl protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:20|
|Immunoprecipitation (IP)||2µg/mg protein lysate|
|Western Blot (WB)||1 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-14398 targets c-Abl in immunofluorescence, immunoprecipitation, immunohistochemistry (paraffin), and Western blot applications and shows reactivity with Human.
The MA5-14398 immunogen is recombinant Abl protein.
The c-Abl proto-oncogene encodes a protein tyrosine kinase that is located in the cytoplasm and nucleus. In chronic myelogenous leukemia and in a subset of acute lymphoblastic leukemias, the c-Abl proto-oncogene undergoes a (9;22) chromosomal translocation producing a novel rearranged chromosome (the Philadelphia chromosome) As the result of the fusion of c-Abl sequences from chromosome 9 to the Bcr gene on chromosome 22. The molecular consequence of this translocation is the generation of a chimeric Bcr/Abl mRNA encoding activated Abl protein tyrosine kinase.
IP-MS enrichment of ABL1 (LFQ intensity): ABL1 was enriched 1119-fold from HCT116 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and ABL1 antibody (Part No. MA5-14398). See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
MA5-14398 was used in immunohistochemistry to perform a phase II clinical trial of imatinib mesylate in patients with recurrent low-grade serous carcinoma of the ovary, peritoneum or fallopian tube
|Noguera IR,Sun CC,Broaddus RR,Branham D,Levenback CF,Ramirez PT,Sood AK,Coleman RL,Gershenson DM||Gynecologic oncology (125:640)||2012|
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
MA5-14398 was used in immunohistochemistry to study the therapeutic efficacy of imatinib mesylate in patients with recurrent ovarian and primary peritoneal cancer
|Coleman RL,Broaddus RR,Bodurka DC,Wolf JK,Burke TW,Kavanagh JJ,Levenback CF,Gershenson DM||Gynecologic oncology (101:126)||2006|
Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
MA5-14398 was used in immunohistochemistry to study the expression of imatinib mesylate-targeted kinases in endometrial carcinoma
|Slomovitz BM,Broaddus RR,Schmandt R,Wu W,Oh JC,Ramondetta LM,Burke TW,Gershenson DM,Lu KH||Gynecologic oncology (95:32)||2004|
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
MA5-14398 was used in immunohistochemistry to study expression of c-ABL, c-KIT, and PDGF receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium
|Schmandt RE,Broaddus R,Lu KH,Shvartsman H,Thornton A,Malpica A,Sun C,Bodurka DC,Gershenson DM||Cancer (98:758)||2003|
|Not Applicable||Not Cited||
Delayed activation of Bax by DNA damage in embryonic stem cells with knock-in mutations of the Abl nuclear localization signals.
MA5-14398 was used in immunocytochemistry to investigate Abl nuclear import in DNA damage-induced apoptosis
|Preyer M,Shu CW,Wang JY||Cell death and differentiation (14:1139)||2007|